glp-1 nejm

glp-1 nejm In the FLOW trial, researchers assessed whether the glucagon-like peptide 1 receptor agonist semaglutide was effective in preventing progression of kidney disease in patients with type 2 diabetes and chronic kidney disease Top Stories in Nephrology 2024

Name: glp-1 nejm In the FLOW trial, researchers assessed whether the glucagon-like peptide 1 receptor agonist semaglutide was effective in preventing progression of kidney disease in patients with type 2 diabetes and chronic kidney disease Top Stories in Nephrology 2024
Brand: clinicadranadircruz.com.br
SKU: 79140914489
Price: 24.56 USD
Availability: InStock
Rating: 4.6426 (10 reviews)

SKU: 79140914489

4.6

USD24.56 USD60.56

Pay in 4 interest-free payments of $6.14 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Oct 20 - Oct 25

Description

Participants were asked whether they had used medication in the past year to manage type 2 diabetes (excluding insulin), reduce the risk of heart disease, or support weight loss and, if so, whether they had used any of five specific GLP-1 or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists